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Inhibition of Hedgehog-dependent tumors and cancer
stem cells by a newly identified naturally occurring
chemotype
Paola Infante1,5, Romina Alfonsi2,5, Cinzia Ingallina1,5, Deborah Quaglio3, Francesca Ghirga1, Ilaria D’Acquarica3, Flavia Bernardi2,
Laura Di Magno1, Gianluca Canettieri2, Isabella Screpanti2,4, Alberto Gulino2, Bruno Botta3, Mattia Mori*,1 and Lucia Di Marcotullio*,2,4
Hedgehog (Hh) inhibitors have emerged as valid tools in the treatment of a wide range of cancers. Indeed, aberrant activation of the
Hh pathway occurring either by ligand-dependent or -independent mechanisms is a key driver in tumorigenesis. The smoothened
(Smo) receptor is one of the main upstream transducers of the Hh signaling and is a validated target for the development of
anticancer compounds, as underlined by the FDA-approved Smo antagonist Vismodegib (GDC-0449/Erivedge) for the treatment of
basal cell carcinoma. However, Smo mutations that confer constitutive activity and drug resistance have emerged during treatment
with Vismodegib. For this reason, the development of new effective Hh inhibitors represents a major challenge for cancer therapy.
Natural products have always represented a unique source of lead structures in drug discovery, and in recent years have been
used to modulate the Hh pathway at multiple levels. Here, starting from an in house library of natural compounds and their
derivatives, we discovered novel chemotypes of Hh inhibitors by mean of virtual screening against the crystallographic structure
of Smo. Hh functional based assay identified the chalcone derivative 12 as the most effective Hh inhibitor within the test set. The
chalcone 12 binds the Smo receptor and promotes the displacement of Bodipy-Cyclopamine in both Smo WT and drug-resistant
Smo mutant. Our molecule stands as a promising Smo antagonist able to specifically impair the growth of Hh-dependent tumor
cells in vitro and in vivo and medulloblastoma stem-like cells and potentially overcome the associated drug resistance.
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Hedgehog (Hh) signaling is amorphogenetic pathway that has
a crucial role during embryonic development and tissues
homeostasis.1–3 In vertebrates, Hh pathway activation is
mediated by two transmembrane receptors: Patched1
(Ptch1), endowed with inhibitory functions, and Smoothened
(Smo), which is the central transducer of Hh pathway and
belongs to the class F (Frizzled) G protein-coupled receptor
family. In physiological conditions, extracellular Hh ligand
(Shh, Ihh, Dhh) binding to Ptch1 protein relieves its repression
to Smo allowing signal transduction and activation of the Gli
transcription factors, which in turn upregulate target genes
involved in the most important cellular processes. Aberrant
activation of Hh signaling is deeply involved in tumorigenesis.
Indeed, activating germline or somatic mutations of genes
encoding Hh pathway components are found in human and
murine basal cell carcinoma (BCC) and medulloblastoma
(MB).4,5 Moreover, uncontrolled Hh signaling has been
reported to drive tumor progression in several cancers,
including lung, breast, stomach, pancreas and hematopoietic
malignancies.6 For this reason, the development of Hh
inhibitors is eliciting great interest in drug discovery. Vismo-
degib (GDC-0449/Erivedge) and others Smo antagonists
have shown promising results in MB and BCC tumors.
However, despite an initial clinical response, a number of
drug-resistant Smo mutations were observed in patients also
in recent clinical trials.7–9 Further, some clinical trials have
failed so far,10–13 due to poor pharmacokinetics, low selectivity
on cancer stem cells (CSCs), and the presence of bystander
co-regulatory mechanisms of the Hh pathway. Indeed, anti-
Smo resistance is mediated by hyperactivation of the powerful
downstream Gli factors due to Gli2 amplification during
Vismodegib or Sonidegib (LDE-225) treatment,4,14 or upregu-
lation of Gli via a non-canonical Hh signaling activation, such
as the induction of phosphoinositide 3-kinase (PI3K) pathway
observed during Sonidegib administration.15,16 Notably,
non-canonical Hh mysregulation can also occur through
Gli-independent events that include Src kinase activation,17
calcium spike activity at the primary cilium,18 activation of the
GTPases Rac1 and RhoA by coupling of Smo to Gi proteins,19
and metabolic reprogramming by cilium-dependent
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Table 1 List of small molecules selected in silico as Smo inhibitors
Mol Common name Chemical structure MW Molecular
formula
Source Ref
1 Myricetin 318.24 C15H10O8 Myrica nagi (Myriaceae) (Perkin and Hummel
39)
2 Naringin 580.53 C27H32O14 Citrus decumana (Rutaceae) (Zoller
40)
3 Martinoside 652.64 C31H40O15 Aegiphila obducta (Verbaceae) (Leitao et al.
41)
4 Cevadine 591.73 C32H49NO9 Veratrum sabadilla (Liliaceae) (Wright and Luff
42)
5 Sorocein B 658.69 C40H34O9 Sorocea bonplandii (Moraceae) (Messana, et al.
43)
6 Sorocein A 630.68 C39H34O8 Sorocea bonplandii (Moraceae) (Messana, et al.
43)
7 Dihydrochalcone 344.36 C19H20O6 Synthetic (Tognazzi
45)
8 Kuwanol E 650.71 C39H38O9 Morus nigra (Moraceae) (Ferrari et al.
38)
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Table 1 (Continued )
Mol Common name Chemical structure MW Molecular
formula
Source Ref
9 Derrustone 326.30 C18H14O6 Derris scandens
(Leguminosae)
(Falshaw et al.37)
10 Hexa-OMe-
Chalcone
388.41 C21H24O7 Synthetic (Bargellini
46)
11 Isosophoranone 438.51 C26H30O6 Sophora tomentosa
(Leguminosae)
(Delle Monache et al.36)
12 Penta-OMe-
chalcone
358.39 C20H22O6 Synthetic (Bargellini and Avrutin
47)
13 Auriculasin 420.45 C25H24O6 Maclura pomifera (Moraceae) (Delle Monache et al.
35)
14 Barbinervic acid 488.70 C30H48O5 Petivera alliacea
(Phytolaccaceae)
(Delle Monache and
Suarez44)
15 Hesperidin 610.56 C28H34O15 Citrus sinensis (Rutaceae) (Higby
34)
16 Cabreuvin 312.32 C18H16O5 Araucaria angustifolia
(Araucariaceae)
(Fonseca et al.33)
17 Jaceidin 360.31 C18H16O8 Tanacetum parthenium
(Asteraceae)
(Long et al.32)
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Smo-Ca2+-AMPK axis.20 These findings raise the need for
new effective Smo antagonists able to escape drug resistance
and to counteract tumor growth.
Natural products are a unique source of remedies and
medicines since ancient times, and still have a key role in
modern drug discovery.21–23 The first Hh inhibitor ever
discovered has been Cyclopamine, an alkaloid isolated from
Veratrum californicum that potently antagonizes Smo and has
efficacy against Hh-dependent tumors.24,25 In recent years,
several natural products have been found to impact on Hh
transduction by direct or indirect mechanisms.26 Of note, in our
previous effort to identify small molecules targeting Gli1/DNA
interaction, the isoflavoneGlaB has been discovered.27 These
evidences clearly indicate that natural products represent a
profitable source of chemotypes to modulate the Hh pathway
at multiple levels.
To this end, an in house library of natural compounds and
their derivatives was screened in silico towards the crystal-
lographic structure of the Smo bound to Cyclopamine.28 Hh
functional based assay identified the chalcone 12 as the most
effective Hh inhibitor within the test set. 12 binds to Smo, is not
sensitive to drug-resistant Smo mutation, and shows anti-
oncogenic activity promoting growth arrest of Hh driven tumor
cells and primary MB cells from Ptch+/− mice, and inhibiting
MB stem-like cells self-renewal.
In summary, in this work we identified the chalcone 12, and
other small molecules, which represent novel natural products
chemotypes of Hh inhibitors.
Results
Virtual screening. To identify natural products chemotypes
of Smo antagonists, an in house library of natural and
synthetic compounds was screened in silico against the
crystallographic structure of Smo bound to Cyclopamine
(PDB: 4O9R).28 Although being of relatively restricted dimen-
sions, the library is endowed with a noticeable chemical
diversity and lead-like features, and has been successfully
used in some computer-based hits/leads discovery
studies.27,29 The FRED docking program (OpenEye) was
used for carrying out docking simulations. Molecules were
Figure 1 Inhibition of endogenous Hh signaling in NIH3T3 Shh-Light II cells and predicted binding mode to Smo. (a and b) Docking-based binding conformation of
compounds 11 and 12 within the antagonists’ site of Smo. The crystallographic structure of Smo encoded by PDB ID: 4O9R was used, and is showed as green cartoon. Residues
within 5 Å from the ligands are showed as green lines. Residues involved in binding to well-known crystallographic Smo antagonists are highlighted as green sticks. Small
molecules are showed as cyan sticks. H-bond interactions are highlighted by black dashed lines. (c–d) Dose–response curve of compound 12 (c) and compound 11 (d) in SAG-
treated in comparison with untreated NIH3T3 Shh-Light II cells. Treatment time was 48 h, and normalization was against Renilla luciferase. Data show the mean±S.D. of three
independent experiments. *Po0.05; **Po0.01 versus SAG
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ranked according to the Chemgauss4 score, and the
predicted binding mode of the top 20% molecules was
visually inspected. Virtual hits fitting the antagonists binding
site of Smo, and interacting with key residues highlighted
by crystallographic studies (namely, N219, Y394, K395,
R400 and E518)28,30,31 were deemed top priority. After a
subsequent analysis of chemical diversity, molecules 1–17
(Table 1) were submitted to functional investigation.
Chemistry. The potential Smo antagonists 1–17 identified in
silico (see Table 1) show a noticeable range of chemical
diversity and differ also for their source, which is either natural
Figure 2 Compound 12 inhibits Hh signaling without affecting AP1/Jun and WNT/β-Catenin pathways. (a) The graphs show the Hh target genes expression levels in
Ptch1− /− MEFs treated for 48 h with 12 or DMSO as control. mRNA levels were determined by quantitative real-time PCR (qRT-PCR) normalized to endogenous control
(β2-microglobulin and HPRT). Pfkfb3 gene was used as negative control. *Po0.05 versus CTR. (b and c) AP1/Jun and WNT/β-Catenin pathways activity were assayed in MEFs
WT transfected with MMP1-luciferase reporter and c-Jun (b) or Top Flash-luciferase reporter and β-Catenin (c), respectively, in the presence or absence of increasing
concentrations of compound 12. Treatment time was 24 h, and normalization was against Renilla luciferase. Data show the mean± S.D. of three independent experiments
Figure 3 Compound 12 inhibition of Bodipy-Cyclopamine (BC) binding to whole cell expressing either Smo WT or Smo D473H. (a) Competitive binding of Bodipy-
Cyclopamine (BC) in HEK293T cells transfected transiently with human WTor mutant Smo (D473H) was conducted with various concentrations of compound 12. BC binding
(green) is visualized using fluorescence microscopy in a representative field. (b) The concentrations–response curves express the percentage of BC incorporation observed after
compound 12 treatment in HEK293T cells transfected with human WT or mutant (D473H) Smo, respectively. Data show the mean± S.D. of three independent experiments.
*Po0.05 versus CTR. Quantitative data are the average BC intensity from five independent fluorescence microscopy images
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or synthetic. Most of them belong to the flavonoids family,
which includes flavonol (namely, 1 and 17), flavanone
(namely, 2 and 15), isoflavon (namely, 9, 13 and 16) and
isoflavanone (namely, 11) derivatives. There are three Diels-
Alder type adducts (namely, 5, 6 and 8) and three chalcones
(namely, 7, 10 and 12). One steroid-derived alkaloid (namely, 4)
and one triterpene (namely, 14) complete the test set,
together with a phenylpropanoid glycoside (namely, 3). The
molecular weights range from about 312 to 658 Da, the
highest values corresponding to the glycosylated (e.g., 2, 3
Figure 4 Compound 12 inhibition of Hh-dependent growth of cerebellum granule cell progenitors. (a and b) BrdU assay in cerebellar granule cell progenitors (GCPs). GCPs
isolated from 4-day-old mice were treated with SAG alone or in combination with compound 12 at 5 and 10 μM concentrations for 48 h. (a) Inhibition of cell proliferation was
measured as percentage of BrdU incorporation in comparison with SAG-treated sample. Data show the mean±S.D. of three independent experiments. *Po0.05 SAG
+compound 12 versus SAG (CTR). (b) The immunofluorescence staining of BrdU (red) and nuclear Hoechst staining (blue) show the decrease of BrdU uptake after compound 12
treatment (5 and 10 μM). (c) qRT-PCR analysis show Hh and proliferation targets mRNA expression levels determined in GCPs culture derived from 4-day-old mouse cerebella
treated with SAG alone or in combination with compound 12 at 5 and 10 μM concentrations for 48 h. In all qRT-PCR experiments, the results were normalized to endogenous
control (β2-microglobulin and HPRT). Shown is the mean of three independent experiments. Error bars indicate S.D. *Po0.05 SAG+compound 12 versus SAG (CTR)
Figure 5 Compound 12 inhibition of Hh-dependent MB tumor cell growth. (a–c) Ex vivo cell cultures from Ptch1+/− mice MBs were treated with compound 12, Cyclopamine,
Vismodegib, LDE-225 or DMSO only. (a and b) After the indicated times, a trypan blue count was performed to determine the growth rate of viable cells. (c)Gli1mRNA expression
levels were determined by qRT-PCR normalized to endogenous control (β2-microglobulin and HPRT). (d–f) Compound 12 inhibits MB-SCs self-renewal. (d) Suspension of single
MB-SCs isolated from Ptch1+/− mice were cultured in stem cell medium to allow the formation of primary neurospheres. Primary neurospheres were dissociated and treated with
increasing concentrations of compound 12, Cyclopamine or DMSO only. After 7 days of treatment, the number of secondary neurospheres derived from a known number of single
cells was counted. The self-renewal MB-SCs’ capability is expressed as percentage of neurosphere-forming cells. (e) Representative bright-field images of tumor neurospheres
after compound 12 or Cyclopamine treatment are also shown. (f) MB-SCs isolated from Ptch1+/− mice MBs were treated for 48 h with compound 12 or DMSO only. qRT-PCR
analysis show Hh, proliferation and stemness target mRNA. For qRT-PCR, results were normalized to endogenous control (β2-microglobulin and HPRT). All data show the
mean± S.D. of three independent experiments. *Po0.05; **Po0.01 versus DMSO (CTR)
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and 15) and Diels-Alder type adducts (namely 5, 6 and 8).
The source of 1–17 are collected in Table 1, together with the
reference data.32–44 7, 10 and 12 are of synthetic origin but
endowed with a natural scaffold, namely chalcone, and have
been synthesized by Claisen–Schmidt reaction, following a
slightly modified procedure developed by Professor Bargellini
(1879–1963).45–47
Identification of Smo antagonists: functional screening,
predicted binding mode and theoretical affinity. The
inhibitory properties of the potential Smo antagonists 1–17
were investigated in a luciferase reporter assay that is widely
used for characterizing Hh inhibitors. NIH3T3 Shh-Light II
cells, stably incorporating a Gli-responsive firefly luciferase
reporter (Gli-RE),25 were treated with the synthetic Smo
agonist SAG24 alone or in combination with the selected
small molecules to evaluate their dose–response ability to
suppress Hh pathway. At the maximum concentration of
30 μM, compounds 1–5 revealed no activity (Supplementary
Figure S1a), whereas 6–10 and 11–12 showed mild and high
activity, respectively (Supplementary Figure S1b and S1c)
with an IC50 range of 4–38 μM (Supplementary Table S1). We
excluded the possibility that inhibition activity in this assay
was mediated by cytotoxicity because no decrease was
shown in the luciferase assay control Renilla as observed
instead for 13–17.
These data were in accordance with the molecular docking
simulations showing that 6–12 and, particularly the most
active 11 and 12 are able to fit the antagonists’ site of Smo,
which is located within its heptahelical bundle, and to establish
interaction with its key residues. In particular, 11 and 12 bind
into the hydrophobic pocket bounded by residues F484, I215,
L221, M301, L303, W480, F222 and Y394. This latter residue
also establishes π–π stacking interaction and an H-bond with
11 and 12 (Figures 1a and b). Additional H-bonds are
established with, N219, Q477, E518 and R400. Notably, these
residues have been already identified in X-ray crystallography
studies as crucial for small molecules binding to Smo.28,30,31
Finally, the binding mode of 11 and 12 is highly comparable
and show a noticeable shape and pharmacophoric over-
lapping each other. The predicted binding mode of molecules
6–10 is reported in Supplementary Figure S2, and is highly
consistent with the above description, even if it is character-
ized by a fewer interactions with Smo residues, as well as with
Figure 6 Compound 12 inhibition of Hh-dependent BCC cell growth in vitro and in vivo. (a–c) Compound 12 inhibition of Hh-dependent BCC tumor cell growth. ASZ001 BCC
cells were treated with compound 12, Cyclopamine, Vismodegib, LDE-225 or DMSO only (a and b). After the indicated times, a trypan blue count was performed to determine the
growth rate. Gli1 mRNA expression levels were determined by qRT-PCR after treatment of ASZ001 BCC cells with compound 12, Cyclopamine, Vismodegib, LDE-225 or DMSO
only (c). Results were normalized to endogenous control (β2-microglobulin and HPRT). All data show the mean± S.D. of three independent experiments. *Po0.05; **Po0.01
versus DMSO (CTR). (d–g) ASZ001 BCC allografts. Change of tumor volume during compound 12 or vehicle treatment period (d). Representative flank allografts average
volumes (e). H&E and immunohistochemical staining of Ki67 of allograft tumor samples (f). Scale bars represent 250 μm for H&E and Ki67. Quantification of Ki67 staining from
immunohistochemistry shown in (f). (g) Shown is the mean± S.D. of tumor (n= 6) for each treatment. *Po0.05 versus CTR
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a worse score than 11 and 12 (Supplementary Table S1). For
the sake of clarity, molecular docking was performed
exclusively against the well-known antagonists site of Smo,
occupied by the natural antagonist Cyclopamine in the
selected X-ray structure.28 Indeed, our biological data convin-
cingly support that Hh inhibitors 11 and 12 interact with Smo
within the same site as Cyclopamine.48
In more detail, a dose–response curve of 11 and 12 in
NIH3T3 Shh-light II cells luciferase assay proved that 12
(2',4',5',3,4-pentamethoxychalcone) was the most powerful in
inhibiting the Hh pathway, with an IC50 of 4.44 μM (Figure 1c
and Supplementary Table S1) while 11, namely isosophor-
anone, showed a lower effect, with an IC50 value of 22.56 μM
(Figure 1d). For this reason, we focused further studies only on
12. To investigate the inhibitory properties of 12 on Hh
pathway, we analyzed endogenous Hh target gene activation
in genetically defined Ptch1− /− mouse embryonic fibroblasts
(Ptch1− /− MEFs) (Figure 2a). In these cells, constitutive
activation of the Hh pathway is the consequence of the loss of
repressive receptor Ptch1 gene, thus determining high
expression levels of Hh target. Compound 12, at a concentra-
tion of 5 μM, significantly reduced mRNA levels of several
endogenous Hh target genes, including Gli1, the most
powerful effector of Hh signaling.5
Importantly, 12 revealed specificity of action for Hh signaling
without affecting luciferase activity driven by Hh-unrelated
(i.e., Jun/AP1) (Figure 2b) and Hh-related (i.e., Wnt/β-catenin)
signaling pathways, respectively (Figure 2c).
Docking-based complexes were further relaxed through
energy minimization in explicit solvent, and their theoretical
affinity to Smo was estimated by means of a rescoring
procedure based on multiple functions (Supplementary Table
S1). The Chemgauss4 and the Chemscore functions proved
to rank correctly the compounds and to discriminate quite well
Hh inhibitors from inactives. In contrast, rescoring with
XSCORE or the Molecular-Mechanics Generalized Born
Surface Area (MM-GBSA) approach provided a worse ranking
of tested compounds (Supplementary Table S1).49–51 This
benchmarking study performed on diverse naturally occurring
chemotypes may facilitate future structure-based virtual
screenings against Smo.
It is worth mentioning that 12 was predicted not to interact
with D473 (Supplementary Figure S3), a key residue
responsible for drug resistance at the Smo receptor upon
mutation to histidine (D473H), as identified in clinical patients
treated with Vismodegib.7 Therefore, it is expected that this
molecule could be active also against the drug-resistant form
of the Smo receptor, thus representing a potential benefit for
clinical applications.
Compound 12 binding to cells expressing Smo wild-type
or drug-resistant Smo mutant. To verify the direct action of
compound 12 on Smo receptor, we carried out a displace-
ment assay based on the use of the Bodipy-Cyclopamine
(BC), a fluorescent derivative of Cyclopamine that interacts
with Smo at the level of its heptahelical bundle.28 Moreover,
Figure 7 Compound 12 inhibition of human Hh-dependent tumor cell growth. Human medulloblastoma DAOY (a and b) or human prostate carcinoma epithelial 22Rv1 cells
(d and e) were treated with compound 12, Cyclopamine, Vismodegib, LDE-225 or DMSO only. After the indicated times, a trypan blue count was performed to determine the
growth rate. Gli1mRNA expression levels were determined by qRT-PCR after treatment of DAOY (c) or 22Rv1 (f) cells with compound 12, Cyclopamine, Vismodegib, LDE-225 or
DMSO only. Results were normalized to endogenous control (β-actin and HPRT). All data show the mean± S.D. of three independent experiments. *Po0.05; **Po0.01 versus
DMSO (CTR)
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we used this assay to verify the ability of 12 to bind both Smo
WT and Smo D473H mutant, the first described human Smo
point mutation, which confers resistance to treatment with the
Smo antagonist Vismodegib.7,52 Indeed, drug-resistance due
to Smo mutations has raised the need to develop novel Smo
antagonists able to overcome this main limitation for the
clinical development of effective anti-Smo molecules.7–9,53
To this end, HEK293T cells transfected with a vector
expressing Smo WT or Smo D473H mutant, were incubated
with BC in the absence or presence of various concentrations
of 12. As shown in Figures 3a and b, 12 revealed comparable
effects on Smo WT and Smo D473H, showing dose-
dependent effects and equal binding affinity corresponding
to similar IC50 values (12 on Smo WT IC50= 24.50 μM, and
on Smo D473H IC50=22.68 μM). Moreover, 12 significantly
inhibited BC binding to murine Smo WT and the mouse
orthologous Smo D477G mutant (Supplementary Figure S4).
Notably, while Vismodegib showed about 1000-fold loss
affinity for the resistant Smo mutants in binding assay, 12
conserved the same affinity (Supplementary Table S2).
These in vitro findings reveal that 12 acts as Smo antagonist
by binding within the Cyclopamine site, and suggest its
potential use for the treatment of cancers that are dependent
on Hh signaling, including Vismodegib-resistant tumors.
Compound 12 inhibits Hh-dependent cell growth of
cerebellar granule cell progenitors. Hh signaling is a
critical regulator of cerebellum development controlling the
proliferation of granule cell progenitors (GCPs) under
Purkinje cell-derived Shh stimuli. Withdrawal of Hh signal,
occurring physiologically after the first post-natal week in
mice,54 causes cell growth arrest and induces their differ-
entiation into mature granules.55 Importantly, genetic and
epigenetic alterations in the Hh pathway are responsible for
the lack of GCPs proliferation arrest, leading to the
tumorigenic conversion of these progenitors, considered as
the cell of origin of MB.56,57 To investigate the biological
effects of 12, we first tested its ability to suppress Hh-
dependent growth in 4-day-old mouse cerebellar progenitors.
While treatment of GCPs with the Smo agonist SAG-
enhanced cell BrdU uptake (Figures 4a and b), the addition
of 12 reduced significantly this activity, decreasing the
proliferation rate in a dose-dependent way (Figures 4a and
b). Accordingly, GCPs treated with 12 displayed reduced
mRNA levels of Hh target genes and markers related to cell
growth (i.e., Gli1, Gli2, Ptch1, Pcna, cyclin D2) correlating the
decrease of GCPs proliferation after 12 treatment with its
inhibitory effects on Hh signature (Figure 4c).
Compound 12 inhibits the growth of Hh-dependent tumor
cells in vitro and in vivo. To verify the efficacy of 12 to
suppress the proliferation of cancer cells in comparison with
other Smo antagonists, we used Hh-dependent tumor cell
models, such as MB, BCC and prostate cancer. Primary
MB cells freshly isolated from Ptch1+/− mice tumors58–60
and treated with 12 showed the significant inhibition
of the proliferation in comparison with other Smo
antagonists (namely, Cyclopamine, Vismodegib and LDE-
-225), as consequence of the decrease of Gli1 mRNA levels
(Figures 5a–c).
Hh signaling has a central role in stem/progenitor cell
maintenance and self-renewal. In several tumors, including
MB, the aberrant activation of Hh signaling contributes to
CSCs proliferation by the Gli mediated regulation of stemness
marker Nanog.61,62 The presence of CSCs in the tumor mass
is amajor cause of resistance and favors tumor relapse,63 thus
representing an attractive druggable targets for anticancer
therapy. Therefore, CSCs appear appealing tools for testing
the therapeutic potential of the 12 herein identified. We show
that 12, but not Cyclopamine, suppressed the clonogenic self-
renewal ability of murine Ptch1+/− MB stem-like cells to form
spheres from single-cell suspension (Figure 5d) and they
appeared reduced in number and size (Figure 5e). Consistent
with these results, 12 reduced Hh pathway activity in MB stem-
like cells as evaluated by the decrease of the pathway
readouts Gli1, Gli2 and Ptch1 mRNAs, stemness markers
(Nanog,Oct4) as well as growth genes expression (cyclins D1
and D2, Pcna) (Figure 5f).
The ability of 12 to inhibit tumor cells proliferation was also
tested in mouse ASZ001 BCC cells, previously characterized
as a specific Hh-dependent tumor cell line harboring Ptch1
deletion.64 12 showed significant efficacy to impair ASZ001
BCC cell growth in vitro compared with Cyclopamine,
Vismodegib and LDE-225 (Figures 6a and b), in agreement
with the decrease of Gli1 mRNA levels observed after drug
treatment (Figure 6c). The inhibitory effect of 12 on tumor
growth was also confirmed in vivo using a BCC allograft
model. To this end, NOD/SCID mice were engrafted with
ASZ001 BCC cells and treated every second day with s.c.
injections of 12 at a concentration of 50 mg/kg or vehicle
alone. During the treatment period, we observed reduction of
tumor cell growth in 12 treated mice compared with the
controls (Figures 6d and e), consistently with decreased
percentage of Ki67 labeling (Figures 6f and g).
To elucidate the anti-proliferative effects of 12 in human
cancer cell lines,65–67 we investigated its ability to block the
growth of MB, BCC and prostate cancer cells, which are
convenient model for monitoring the pharmacological inhibi-
tion of the Hh pathway.68,69 As shown in Figure 7, 12 displayed
an higher activity than other Smo antagonists in inhibiting
DAOYand 22Rv1 cell proliferation (Figures 7a and b, d and e),
consistent with the significant decrease of Gli1 mRNA levels
after treatment (Figures 7c and f). Similar results were
obtained in human BCC TE354T cell line, previously
described as Hh-dependent cells,70 in which 12 was com-
pared with Vismodegib (Supplementary Figure S5). Overall,
these results confirmed that 12 inhibits the proliferation of Hh-
driven tumor cells.
Discussion
In this study, we identified novel naturally occurring chemo-
types of Hh inhibitors by mean of an integrated multi-
disciplinary study mixing molecular modeling with chemistry,
molecular and cell biology. Particularly, the 2’,4’,5’,3,4-
pentamethoxychalcone (12), was the most potent Hh inhibitor
identified herein, and proved to impair the growth of Hh-
dependent tumor cells in vitro and in vivo.
In this study, we also pinpointed the relevance of natural
products as useful source for drug discovery in cancer therapy.
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In fact, natural products represent more than one-third of all
FDA-approved new molecular entities, and one-quarter of
these derived from plants.21 Near the end of the Twentieth
century, the use of natural products seriously declined in favor
of new emerging technologies to generate drug candidates.
However, these strategies did not deliver the expected
results and recently there has been a renewed interest in the
use of natural products.23,41,71,72 Particularly, chemistry has
emerged as the preferred tool to modify natural products up to
suitable drug candidates, as underlined by the Cyclopamine
derivative IPI–926, which has recently completed phase II
clinical trials.73
Cancer is one of the main human diseases for which natural
products find therapeutic applications. In this context, the
morphogenetic Hh signaling represents a noticeable example
of druggable tumorigenic pathway. In the past years, many
research efforts have been spent in the identification of Hh
antagonists able to suppress the aberrant activation of this
signaling occurred in several disparate human tumors. The first
Hh inhibitor ever discovered has been Cyclopamine, an
alkaloid isolated from Veratrum californicum that antagonizes
Smo and has efficacy against Hh-dependent tumors.25 More-
over, the isoflavone genistein, first isolated in Genista tinctoria
and naturally occurring in several plants including tobacco and
maize, inhibits weakly the Hh pathway.74 Other natural
products have been found to impair Hh transduction by acting
on the main positive regulators of this signaling, both upstream
on Smo69 and downstream on the transcription factor Gli1.12,27
Recently, the clinical development of Smo antagonists has
proved disappointing because their scarce pharmacokinetics,
severe side effects, and the emergence of drug resistance due
to point mutations that rendered Smo insensitive to the drugs.
With the aim to identify natural products as new Smo
antagonists able to overcome these limits, we performed a
docking-based virtual screening of an in house library of
natural compounds and their derivatives, composed of about
1200 small molecules of natural or synthetic origin. This
structure-based approach significantly beneficed of the
crystallographic structure of Smo bound to the natural
antagonist Cyclopamine. Seventeen compounds selected
in silico were subsequently screened for their ability to
counteract Hh activity by a luciferase functional assay in
NIH3T3 Shh-Light II cells. According to this in vitro assay, five
compounds (1–5) were inactive, five (6–10) showed mild
activity and two (11–12) revealed high activity, whereas 13–17
resulted toxic. The dose–response activity of chalcone 12, the
most effective molecule here identified, was supported by the
demonstration of its direct binding to Smo receptor, as
predicted by molecular modeling and confirmed in a displace-
ment assay with BC. More interestingly, 12 resulted active on
the D473H drug-resistant Smo mutant, the main cause of
failure of the Vismodegib treatment, suggesting the possible
therapeutic applicability of 12 for the treatment of Vismodegib-
resistant tumors.75 The strong effect of 12 to inhibit Hh activity
compared with BC displacement assay supposed its ability to
affect other positive regulators of the Hh signaling. In this
regard, 12 suppressed the expression of endogenous Hh
target genes in Ptch1− /−, as well as in SuFu− /− MEFs
(Supplementary Figure S6),76 two cell models in which the
constitutive activation of Hh signaling is consequence of the
genetic ablations of the upstream Ptch1 and the downstream
SuFu-negative regulators, respectively.
Hh inhibition by 12 was also observed in the physiological
cellular context of GCPs, whose proliferation is under Hh
pathway controls during the cerebellum development. Indeed,
12 suppressed Hh gene signature in SAG-treated GCPs cells,
with the consequent decrease of their proliferation. Note-
worthy, 12 demonstrated specificity of action for Hh signaling,
resulting inactive on both Hh-related and -unrelated pathways,
such as Wnt/β-catenin and Jun/AP1 signaling, respectively.
Aberrant activation of Hh pathway leads to tumorigenesis by
ligand-independent mutational activation of the Hh signaling
or ligand-dependent paracrine signaling.77 In the paracrine
model of Hh-dependent oncogenesis, the ligand produced by
tumor-derived cells signals to the surrounding stromal cells
and indirectly promotes tumor growth. Here, we demonstrate
the ability of 12 to selectively inhibit theGli1mRNA expression
and the proliferation of Hh-dependent tumor cells in vitro and
in vivo, including MB and BCC, two tumor models where Hh
pathway activity occurs by ligand-independent manner. The
effect of our compound in tumor models displaying ligand-
dependent Hh pathway activation such as colorectal, pan-
creatic and bladder cancer, would be interesting to be
investigated.
Overall, our findings underline the relevance of natural
products as useful source for drug discovery in cancer therapy,
and discover a new specific Smo antagonist that inhibits the
Hh-dependent tumor cells growth, and stands as a valuable
starting point to develop potential therapeutic agents for
Vismodegib- or Sonidegib-resistant tumors.
Experimental section
Chemistry. Source of compounds 1–17. All the tested compounds (namely,
1–17) are known structures which belong to our in house library of natural products.
Chemical identity of compounds 1–17 was assessed by re-running NMR
experiments, which proved to be in agreement with the literature data reported
below for each compound. The purity of all compounds, checked by reversed-phase
HPLC under the chromatographic conditions reported in the Supporting Information,
was always higher than 95%.
Compound 1 (myricetin or 3,5,7-trihydroxy-2-(3,4,5-trihydroxy-phenyl)-4H-chro-
men-4-one) was purchased from Sigma Aldrich, St. Louis, MO, USA, as used without
further modification.
Compound 2 (naringin or (2S)-7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxy-
methyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-
hydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one was purchased from Sigma-
Aldrich, as used without further modification.
Compound 3 (martinoside or [(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(3-hydroxy-4-
methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-
methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate)
showed NMR spectra identical to the literature.41
Compound 4 (cevadine or (3β,4α,9β,16β)-4,12,14,16,17,20-hexahydroxy-4,9-
epoxycevan-3-yl (2Z)-2-methyl-2-butenoate) showed NMR spectra identical to the
literature.78
Compound 5 (sorocein B or (2E)-1-[(3aS,13bS,13cR)-4,11-dihydroxy-8a-(5-
hydroxy-2,2-dimethyl-2H-chromen-8-yl)-2-methyl-1,8a,13b,13c-tetrahydro-3aH-
benzo[3,4]isochromeno[1,8-bc]chromen-5-yl]-3-(2,4-dihydroxyphenyl)-2-propen-1-
one) showed NMR spectra identical to the literature.43
Compound 6 (sorocein A or (3aS,13bS,13cR)-6-[(E)-2-(2,4-dihydroxyphenyl)
vinyl]-8a-(5-hydroxy-2,2-dimethyl-2H-chromen-8-yl)-2-methyl-1,8a,13b,13c-tetrahy-
dro-3aH-benzo[3,4]isochromeno[1,8-bc]chromene-4,11-diol) showed NMR spectra
identical to the literature.43
Compound 7 (dihydrochalcone or 3-benzo[1,3]dioxol-5-yl-1-(2,4,5-trimethoxy-
phenyl)-propan-1-one) showed NMR spectra identical to the literature.79
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Compound 8 (kuwanol E or [2,4-dihydroxy-3-(3-methyl-2-buten-1-yl)phenyl]
[(1R,2S,6S)-6-(2,4-dihydroxyphenyl)-2-{4-[(E)-2-(2,4-dihydroxyphenyl)vinyl]-2,6-dihy-
droxyphenyl}-4-methyl-3-cyclohexen-1-yl]methanone) showed NMR spectra identical
to the literature.80
Compound 9 (derrustone or 3-(1,3-benzodioxol-5-yl)-5,7-dimethoxy-4H-chromen-
4-one) showed NMR spectra identical to the literature.81
Compound 10 (2’,3’,4’,6’,3,4-hexamethoxychalcone or 3-(3,4-dimethoxy-phenyl)-
1-(2,3,4,6-tetramethoxy-phenyl)-2-propen-1-one) showed NMR spectra identical to
the literature.79
Compound 11 (isosophoranone or 5,7-dihydroxy-3-[4-hydroxy-2-methoxy-3-(3-
methyl-2-buten-1-yl)phenyl]-6-(3-methyl-2-buten-1-yl)-2,3-dihydro-4H-chromen-4-
one) showed NMR spectra identical to the literature.82–84
Compound 12 (2’,4’,5’,3,4-pentamethoxychalcone or 3-(3,4-dimethoxy-phenyl)-1-
(2,4,5-trimethoxy-phenyl)-2-propen-1-one) showed NMR spectra identical to the
literature.79
Compound 13 (auriculasin or 7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-
(3-methyl-2-buten-1-yl)-2H,6H-pyrano[3,2-g]chromen-6-one) showed NMR spectra
identical to the literature.35
Compound 14 (barbinervic acid or (1R,2R,4aS,6aR,6aS,6bR,8aR,9S,10R,12aR,
14bS)-1,10-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,
8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid) showed NMR spectra
identical to the literature.85
Compound 15 (hesperidin or (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methy-
loxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one) was purchased from
Sigma-Aldrich, as used without further modification.
Compound 16 (cabreuvin or 3-(3,4-dimethoxyphenyl)-7-methoxy-4H-chromen-4-
one) showed NMR spectra identical to the literature.33
Compound 17 (jaceidin or 5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,6-
dimethoxy-4H-chromen-4-one) showed NMR spectra identical to the literature.32
Molecular modeling. The main features of the in house library of natural
compounds and their derivatives have been already described elsewhere.27,29
Conformational analysis was performed with OMEGA2 from OpenEye,86,87 keeping
all parameters at their default values and allowing the storage of up to 600
conformers of each molecule in the final database. Hydrogen sampling options were
activated. The receptor for molecular docking simulations was prepared with the
make_receptor utility of OEDocking. Molecular docking was performed with the
FRED docking program (OpenEye),88–90 using the highest-resolution settings.
During virtual screening, only the best pose of each compound was saved and
virtual Smo antagonists were ranked according to the Chemgauss4 score. In
subsequent accurate docking simulations, up to 10 poses of each molecule were
stored. Energy minimization of docking complexed was performed with Amber12.91
In detail, Smo/ligand complexes were solvated in a rectilinear box of TIP3P typed
water molecules buffering 4Å from the protein. The solvent was first energy
minimized for 100 steps with the Steepest Descent algorithm (S.D.) and for
subsequent 200 steps with the Conjugate Gradient algorithm (CG) before to energy
minimize the solvated solute for 1000 steps S.D. and subsequent 4000 steps CG.
Rescoring was performed with multiple programs and functions including
XSCORE,49 Chemscore,92 and the MM GBSA method implemented in Amber12,
using settings previously described.50,91,93
Biology
Cell cultures, transfection and treatments: HEK293T, Shh-Light II, Ptch1–/–
MEFs, SuFu–/– MEFs, wild-type MEFs and 22Rv1 cells were cultured in DMEM plus
10% FBS. DAOY cells were maintained in Eagle's Minimum Essential Medium
(MEM) plus 10% FBS. All media contained L–glutamine and antibiotics. ASZ001
BCC cells were cultured in 154CF medium (Gibco-BRL, Grand Island, NY, USA)
plus 2% FBS chelated with Chelex 100 sodium form (Sigma Aldrich), calcium
chloride 0.05 mM (Gibco-BRL) and antibiotics. Cerebellar GCPs (from 4-days-old
mice) were isolated and cultured as previously described.94 TE354T human
BCC cells (ATCC CRL–7762) were cultured in DMEM medium (ATCC 30–2002)
plus 10% FBS and antibiotics. Murine MBs were isolated from Ptch1+/– mice (The
Jackson Laboratory, Bar Harbor, ME, USA). Tissues were collected as previously
described,27 and immediately prepared cell suspensions were used for short-term
cultures to keep Hh-sensitivity in vitro.58–60 Transient transfections were performed
using DreamFectTM Gold transfection reagent (Oz Biosciences SAS, Marseille,
France). Cells were treated with SAG (200 nM, Alexis Biochemicals Farmingdale,
NY, USA), Bodipy-Cyclopamine (5 nM, BioVision Inc., San Francisco, CA, USA),
Cyclopamine (Calbiochem, Nottingham, UK), Vismodegib (Selleckchem, Munich,
Germany), LDE-225 (Selleckchem, Munich, Germany).
Hh-dependent luciferase reporter assay: The luciferase assay was
performed in Shh-Light II cells, stably incorporating a Gli-responsive luciferase
reporter and the pRL-TK Renilla (normalization control), treated for 48 h with SAG
(200 nM) and the studied compounds. Luciferase and Renilla activity were assayed
with a dual-luciferase assay system according to the manufacturer’s instruction
(Biotium Inc., Hayward, CA, USA). Results are expressed as luciferase/Renilla
ratios and represent the mean± S.D. of three experiments, each performed in
triplicate.
Bodipy-Cyclopamine (BC) binding assay: Human Myc-DDK-tagged Smo
WT or human Myc-DDK-tagged Smo D473H or mouse Flag-tagged Smo WT or
Flag-tagged Smo-D477G mutant were transfected in HEK293T cells. Cells were
washed in PBS supplemented with 0.5% fetal bovine serum, fixed in 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 10 min, and incubated for
2 h at 37 °C both in the same medium supplemented with Bodipy-Cyclopamine
(5 nM) and the studied compounds. The cells were permeabilized with Triton X100
(Sigma) 0.2%. Dako Fluorescent mounting (Dako, Carpinteria, CA, USA) was used
as mounting medium and Hoechst reagent for staining of the cell nuclei. Bodipy
(green) and Hoechst (blue) signals were analyzed in three to four representative
fields per coverslip (×20 magnification, 1000 cells/field). Data were expressed as
percentage of BC incorporation observed with BC alone.95
mRNA expression analysis: Total RNA was isolated with Trizol (Invitrogen/Life
Technologies, Carlsbad, CA, USA) and reverse transcribed with SensiFAST
cDNA Synthesis Kit (Bioline Reagents Limited, London, UK). Quantitative real-time
PCR (Q-PCR) analysis of Gli1, Gli2, Ptch1, Bmp2, Pfkfb3, CycD1, CycD2, Pcna,
Oct4, Nanog, β-2 microglobulin, β-actin and HPRT mRNA expression was
performed on each cDNA sample using the VIIA7 Real Time PCR System
employing Assay-on-Demand Reagents (Life Technologies). A reaction mixture
containing cDNA template, SensiFAST Probe Lo-ROX Kit (Bioline Reagents
Limited) and primer probe mixture was amplified using FAST Q-PCR thermal cycler
parameters. Each amplification reaction was performed in triplicate and the average
of the three threshold cycles was used to calculate the amount of transcript in the
sample (using SDS version 2.3 software). mRNA quantification was expressed, in
arbitrary units, as the ratio of the sample quantity to the quantity of the calibrator. All
values were normalized with two endogenous controls, β-2 microglobulin or β-actin
and HPRT, which yielded similar results.
Cell proliferation and MB stem cells neurosphere-forming assay: Cell
proliferation was evaluated by BrdU detection (Roche, Welwyn Garden City, UK).
Briefly, after the BrdU pulse (24 h for GCPs) cells were fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton X-100, and BrdU detection
was performed according to the manufacturer’s instructions. Nuclei were
counterstained with Hoechst reagent. At least 500 nuclei were counted in triplicate,
and the number of BrdU-positive nuclei was recorded. To determine the growth rate
of viable cells, a trypan blue count was performed after a treatment period of 24–
48–72 h with studied compound. For the neurosphere-forming assay, cells were
plated at clonal density (1–2 cells/mm2) into 96-well plates and cultured in selective
medium as previously described.62
Allograft experiment: A total of 2 × 106 ASZ001 BCC cells were resuspended in
an equal volume of 154CF medium and Matrigel (BD Biosciences, Heidelberg,
Germany) and injected s.c. at the posterior flank of female NOD/SCID mice
(Charles River Laboratories, Lecco, Italy), as previously described.96 Tumors were
grown until a median size of ~ 200 mm3. Animals were randomly divided into two
groups (n= 6) and treated with solvent only (DMSO-Miglyol, 1:5) (Miglyol 812N by
CREMER OLEO GmbH & Co. KG, Hamburg, Deutschland) or 12 in solvent (50 mg/
kg) for 18 days. Tumor growth was monitored by measuring the size by caliper.
Tumor volumes change was calculated by the formula length × width × 0.5 × (length
+width).97 All animal experiments were approved by local ethics authorities.
Immunohistochemistry: For immunohistochemical staining tissues were for-
malin fixed and paraffin embedded. Sections were incubated with (1:100) rabbit
monoclonal Ki67 antibody (Thermo Fisher Scientific, MA, USA) diluted in PBS.
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Detection was carried out with the mouse-to-mouse HRP (DAB) staining system
(ScyTek Laboratories, Logan, UT, USA) accordingly to the manufacturer's instructions.
Statistical analysis: Statistical analysis was performed using StatView 4.1
software (Abacus Concepts Inc., Piscataway, NJ, USA). Statistical differences were
analyzed with the Mann–Whitney U-test for nonparametric values, and a Po0.05
was considered significant. Results are expressed as mean±S.D. from an
appropriate number of experiments (at least three biological replicas).
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